Neoplasia is one of those “foundation” topics that quietly shows up everywhere on Step 1: pathology, genetics, pharmacology, even immunology. If you can clearly separate benign vs malignant, understand how tumors grow and spread, and recognize the classic high-yield buzzwords, you’ll pick up easy points across many question blocks.
What Is Neoplasia?
A neoplasm is an abnormal mass of tissue whose growth exceeds and is uncoordinated with that of normal tissues, and persists even after the inciting stimulus is removed.
Key idea: neoplasia reflects clonal expansion of a single abnormal cell that acquired driver mutations (growth advantage).
Core Definitions (Step 1 Language)
- Neoplasm: “new growth” (tumor); can be benign or malignant.
- Cancer: a malignant neoplasm.
- Parenchyma: neoplastic cells (determines behavior and diagnosis).
- Stroma: supporting tissue (blood vessels, fibroblasts, ECM); required for growth.
First Aid cross-reference: Pathology → Neoplasia (general principles; benign vs malignant; nomenclature; invasion/metastasis; grading/staging; oncogenes/tumor suppressors).
Benign vs Malignant: The Big Picture
The “Rule of Thumb” Table
| Feature | Benign | Malignant |
|---|---|---|
| Differentiation | Well-differentiated (resembles tissue of origin) | Variable, often poorly differentiated/anaplastic |
| Growth rate | Slow | Faster (but variable) |
| Local invasion | No invasion; often encapsulated | Invades surrounding tissue |
| Metastasis | Absent | Present (key defining feature) |
| Mitoses | Few, normal | Increased; may be atypical |
| Necrosis/hemorrhage | Uncommon | More common (outgrows blood supply) |
| Recurrence after excision | Uncommon | More common |
High-yield Step 1 line: Metastasis is the most reliable sign of malignancy.
Nomenclature You Must Know
Benign Tumors
- Mesenchymal (connective tissue): ends in -oma
- Examples: lipoma, fibroma, leiomyoma
- Epithelial: often adenoma (glandular) or papilloma (finger-like projections)
- Examples: adenoma, papilloma, cystadenoma
Malignant Tumors
- Carcinoma = malignant tumor of epithelial origin
- Examples: adenocarcinoma, squamous cell carcinoma
- Sarcoma = malignant tumor of mesenchymal origin
- Examples: osteosarcoma, liposarcoma, leiomyosarcoma
- Leukemia = malignant hematologic cells in blood/bone marrow
- Lymphoma = malignant lymphoid tissue mass
Classic “Exceptions” (High-Yield)
Some tumors sound benign but are malignant:
- Melanoma
- Lymphoma
- Mesothelioma
- Seminoma
- Hepatoma (hepatocellular carcinoma; older term)
- Glioma (many are malignant/infiltrative)
First Aid cross-reference: Pathology → Neoplasia → Nomenclature + exceptions.
Pathophysiology: How Tumors Become “Cancer”
Cancer is fundamentally a genetic disease of accumulated mutations leading to:
- Unregulated proliferation
- Evasion of growth suppressors
- Resistance to apoptosis
- Replicative immortality
- Angiogenesis
- Invasion and metastasis
- Immune evasion
- Deregulated metabolism (Warburg effect)
Oncogenes vs Tumor Suppressors (Step 1 Framework)
- Oncogenes: gain-of-function; “gas pedal stuck”
- Typically one allele is enough (dominant at cellular level)
- Example themes: growth factor signaling, tyrosine kinases, transcription factors
- Tumor suppressor genes: loss-of-function; “brakes fail”
- Usually need two hits (Knudson hypothesis)
- Examples include cell cycle checkpoints and DNA repair control
First Aid cross-reference: Pathology/Genetics → Oncogenes and tumor suppressors; DNA repair defects.
Clonal Evolution (Why Cancers Get Worse Over Time)
A tumor starts from a single clone, but continued mutation + selection leads to subclones that may:
- grow faster
- resist therapy
- metastasize
This is why targeted therapies can work initially but fail later.
Benign vs Malignant Histology: What Pathologists Look For
Differentiation and Anaplasia
- Differentiation: resemblance to normal tissue (structure and function)
- Anaplasia: lack of differentiation; strongly suggests malignancy
High-Yield Anaplasia Features
- Pleomorphism (variation in cell size/shape)
- Hyperchromatic nuclei
- High nuclear-to-cytoplasmic ratio
- Prominent nucleoli
- Numerous mitoses (especially atypical)
- Tumor giant cells
- Loss of polarity (disorganized architecture)
Dysplasia vs Carcinoma in Situ (CIS)
- Dysplasia: disordered growth; can be reversible if mild and stimulus removed
- Carcinoma in situ: full-thickness dysplasia with intact basement membrane
- No invasion yet, but high risk of progression if untreated
First Aid cross-reference: Pathology → Neoplasia → dysplasia, CIS, invasion.
Invasion and Metastasis (The Money Topic)
How Tumors Invade
Invasion is a multistep process:
- Detach from neighboring cells (often ↓ E-cadherin)
- Degrade basement membrane/ECM (matrix metalloproteinases—MMPs)
- Attach to new ECM components
- Migrate through stroma
High-yield association: Loss of E-cadherin is linked to increased invasiveness (classically in diffuse gastric carcinoma and lobular breast carcinoma, but concept is universal).
Metastasis: Where Tumors Like to Go
Routes:
- Lymphatic spread: typical for carcinomas
- Hematogenous spread: typical for sarcomas (via veins)
- Seeding of body cavities: e.g., ovarian cancer → peritoneum
Sentinel Lymph Node
- First draining node; biopsy helps stage and guide management (especially breast, melanoma).
Classic Organ Tropisms (Very Testable)
- Many cancers → liver (portal drainage) and lungs (systemic venous drainage)
- Prostate → bone (often osteoblastic lesions)
- Breast → bone (often osteolytic), lungs, liver, brain
- Colon → liver
- Renal cell carcinoma → renal vein → IVC → lungs
First Aid cross-reference: Pathology → Neoplasia → metastasis patterns; lymphatic vs hematogenous.
Clinical Presentation: How Neoplasia Shows Up in Patients
Local Effects
- Mass effect: obstruction (colon), increased intracranial pressure (brain tumors)
- Ulceration/bleeding (GI tumors)
- Compression of nerves/vessels
Systemic Effects (Cancer “Constitutional” Symptoms)
- Weight loss, fatigue
- Fever/night sweats (classically lymphomas)
Paraneoplastic Syndromes (High-Yield Step 1 Gold)
Tumor causes symptoms not explained by local invasion/metastasis—often due to ectopic hormone or immune cross-reactivity.
Common themes:
- Small cell lung carcinoma: ectopic ACTH, SIADH; Lambert-Eaton
- Squamous cell carcinoma (lung): PTHrP → hypercalcemia
- Renal cell carcinoma: EPO → polycythemia; paraneoplastic syndromes
- Oat cell (small cell) and others: neurologic paraneoplastic syndromes
First Aid cross-reference: Pathology → Neoplasia → paraneoplastic syndromes; lung cancer associations.
Diagnosis: How We Confirm Benign vs Malignant
Screening vs Diagnostic Tests
- Screening: applied to asymptomatic populations (Pap smear, mammography, colonoscopy)
- Diagnosis: tissue diagnosis is king—biopsy is definitive
Core Path Tools
- Histopathology (H&E): architecture + cytology
- Immunohistochemistry (IHC): lineage markers (e.g., cytokeratin for carcinomas, vimentin for mesenchymal—conceptual)
- Flow cytometry: hematologic malignancies
- Molecular testing: driver mutations, translocations (guides prognosis/therapy)
- Tumor markers: usually for monitoring, not primary diagnosis
Tumor Markers: High-Yield Use
They are best for:
- tracking treatment response
- detecting recurrence
Examples Step 1 loves:
- PSA (prostate)
- CEA (colon/pancreas; not specific)
- AFP (HCC, yolk sac)
- CA-125 (ovarian)
- CA 19-9 (pancreatic)
- β-hCG (choriocarcinoma, germ cell tumors)
First Aid cross-reference: Pathology → Neoplasia → tumor markers; screening tests.
Grading vs Staging (Don’t Mix These Up)
Grade = Microscopic Aggressiveness
- Differentiation
- Mitotic rate
- Nuclear pleomorphism
- Necrosis
Stage = Extent of Spread (Most Important Prognostically)
Typically TNM:
- T: tumor size/local invasion
- N: lymph node involvement
- M: distant metastasis
High-yield: Stage generally predicts prognosis better than grade for most cancers.
First Aid cross-reference: Pathology → Neoplasia → grading and staging.
Treatment Overview (Step 1-Relevant Principles)
You won’t be managing chemo regimens in detail on Step 1, but you will be tested on broad principles and complications.
Main Modalities
- Surgery: best for localized tumors
- Radiation therapy: local control; DNA damage via free radicals
- Chemotherapy: systemic; targets rapidly dividing cells
- Targeted therapy: blocks specific drivers (e.g., tyrosine kinases)
- Immunotherapy: checkpoint inhibitors, monoclonal antibodies, CAR-T (more Step 2/clinical, but increasingly Step 1-adjacent)
High-Yield Complications
- Tumor lysis syndrome (especially leukemias/lymphomas after chemo):
- Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, AKI
- Febrile neutropenia after chemo (Step 2 heavy)
- Secondary malignancies after chemo/radiation (long-term)
First Aid cross-reference: Pharm → antineoplastics; Pathology → Neoplasia → tumor lysis.
High-Yield “Benign vs Malignant” Differentials That Show Up in Vignettes
Clues Favoring Benign
- Slow-growing, well-circumscribed, encapsulated mass
- Histology: uniform cells, rare normal mitoses
- No invasion through basement membrane
Clues Favoring Malignant
- Weight loss, night sweats, anemia of chronic disease
- Irregular borders, fixation to underlying tissues
- Histology: pleomorphism, atypical mitoses, necrosis
- Evidence of metastasis (nodes, liver lesions, lung nodules)
Rapid Review: Step 1 Must-Remember List
- Metastasis = malignant (most reliable indicator).
- CIS = full-thickness dysplasia without basement membrane invasion.
- Carcinoma (epithelial) vs sarcoma (mesenchymal).
- Malignant “-oma” exceptions: melanoma, lymphoma, mesothelioma, seminoma.
- Grading = how ugly under microscope; staging = how far it spread (most prognostic).
- Angiogenesis is required for tumor growth beyond a small size; tumors can outgrow blood supply → necrosis.
- Paraneoplastic syndromes are frequently tested and can be the first clue to an occult malignancy.
First Aid Cross-Reference Map (Quick Navigation)
While page numbers vary by edition, the high-yield First Aid locations are consistently grouped:
- Pathology → General Principles → Neoplasia
- benign vs malignant features
- nomenclature and “-oma” exceptions
- dysplasia/CIS/invasion/metastasis
- grading vs staging
- tumor markers
- Genetics → Oncogenes, Tumor Suppressors, DNA Repair
- Pharmacology → Antineoplastic Drugs
- mechanisms + toxicities
- tumor lysis syndrome